Ovid Therapeutics GAAP EPS of -$0.17 misses by $0.02, revenue of $0.13M misses by $0.04M

* Ovid Therapeutics press release [https://seekingalpha.com/pr/20303367-ovid-therapeutics-announces-planned-leadership-succession-and-reports-business-updates-and] (OVID [https://seekingalpha.com/symbol/OVID]): Q3 GAAP EPS of -$0.17 misses by $0.02.
* Revenue of $0.13M (-23.5% Y/Y) misses by $0.04M.
* Cash, cash equivalents and marketable securities as of September 30, 2025 totaled $25.6 million.

MORE ON OVID THERAPEUTICS

* Ovid Therapeutics Inc. (OVID) Special Call - Slideshow [https://seekingalpha.com/article/4827784-ovid-therapeutics-inc-ovid-special-call-slideshow]
* Ovid Therapeutics: OV329 Promising For Neuronal Excitability In Neurological Disorders [https://seekingalpha.com/article/4827760-ovid-therapeutics-ov329-promising-for-neuronal-excitability-in-neurological-disorders]
* Ovid Therapeutics Inc. (OVID) OV329 Topline Results Webcast from the Phase 1 Healthy Volunteer Study Transcript [https://seekingalpha.com/article/4827705-ovid-therapeutics-inc-ovid-ov329-topline-results-webcast-from-the-phase-1-healthy-volunteer-study-transcript]
* Ovid spikes as Wedbush moves to Outperform on lead asset [https://seekingalpha.com/news/4503059-ovid-spikes-wedbush-moves-outperform]
* Ovid rises after positive results from epilepsy study [https://seekingalpha.com/news/4501691-ovid-rises-after-positive-results-from-epilepsy-study]